@article{2063b3d5c8444dadbb6ad94f79892eb7,
title = "Primed status of transitional B cells associated with their presence in the cerebrospinal fluid in early phases of multiple sclerosis",
abstract = "In the present study we showed that transitional B cells of patients with clinically isolated syndrome (CIS) and relapsing-remitting multiple sclerosis (RR-MS) are reduced in the peripheral blood (PB) (5.5- and 3.7-fold, respectively). In addition, these cells appeared to up-regulate different integrins (α4 and β1). These observations were associated with a primed cellular status, confirmed by an increased proportion of circulating CD80+ transitional B cells. Interestingly, these results correlate with presence of transitional B cells in the CSF. Furthermore, these cells were absent in the CSF of individuals with other inflammatory neurological disease, and their levels in paired PB and CD80 expression were normal. Altogether, our data revealed that a differential primed status of transitional B cells is a characteristic feature of early phases of MS disease, and this functional status is associated with the ability of these cells to cross the blood-CSF barrier.",
keywords = "Cerebrospinal fluid, Clinically isolated syndrome, Integrins, Multiple sclerosis, Transitional B-cell",
author = "{Lee Chang}, Catalina and Isabelle Top and H{\'e}l{\`e}ne Z{\'e}phir and Sylvain Dubucquoi and Jacques Trauet and Patricia Dussart and Lionel Prin and Patrick Vermersch",
note = "Funding Information: We greatly acknowledge Olivier Outteryck, MD, and Anne-Sophie Berteloot, MD, as well as all interns and nurses (Neurologie D Service, P{\^o}le de Neurologie, CHRU of Lille) for assistance with patient recruitment and managing the hard task of sample supply. We also thank Miriam Labalette, MD, PhD, and her collaborators (P{\^o}le d'Immunologie EA2686, CHRU of Lille) for her technical support concerning the flow cytometry platform, and B{\'e}n{\'e}dicte Oxombre-Vanteghem, PhD, for critical review of this manuscript. This work was supported by the Conseil R{\'e}gional Nord-Pas-de-Calais and Centre Hospitalier R{\'e}gionale et Universitaire (CHRU) of Lille , the Bureau Biologie Sant{\'e} (Conseil R{\'e}gionale Nord-Pas-de-Calais) , and Bayer-Schering-Pharma . The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. ",
year = "2011",
month = apr,
doi = "10.1016/j.clim.2010.11.004",
language = "English (US)",
volume = "139",
pages = "12--20",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "1",
}